Page 6 - Yates Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering February 03, 2021 20:44 ET | Source: Sensei Biotherapeutics Sensei Biotherapeutics Gaithersburg, Maryland, UNITED STATES BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of $19.00 p...

Press release content from Business Wire. The AP news staff was not involved in its creation. Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer February 4, 2021 GMT Catamaran CEO Alvin Shih (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 4, 2021-- Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need, today announced the appointment of Alvin Shih, MD, MBA, as President and Chief Executive Officer. He has concurrently been appointed to the Board of...

News Category Global Banking & Finance Reviews Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells -Phase 1a trial achieved primary objective of safety and tolerability -PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases -PT101 maintained selectivity for regulatory T cells at all doses tested -Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-...